RxDoctor Payments Data

Yan Li

Family Medicine · Plano, TXNPI 1619932076

Payments from drug & device makers

$18,126in general payments, 2019–2025

Across 775 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Gilead$2K
  • Boehringer Ingelheim$958
  • Amarin Pharma, Inc.$901
  • plus $8K from 52 others

What the payments were for

  • Consulting fees$1,2007%
  • Travel & lodging$3042%
  • Food & beverage$16,54891%
  • Education$310%
  • Other$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,126 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$325,633
Medicare patients
332
Services billed
7,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol187$258,192
ProliaDenosumab62$106,756
JardianceEmpagliflozin59$94,771
VascepaIcosapent Ethyl95$75,671
OzempicSemaglutide51$63,557
JanuviaSitagliptin Phosphate51$59,018
MounjaroTirzepatide34$53,879
EliquisApixaban30$47,800
KerendiaFinerenone23$33,852
Repatha SureclickEvolocumab16$22,840
Omega-3 Acid Ethyl Esters114$21,063
LinzessLinaclotide14$20,716
RybelsusSemaglutide13$20,258
Soliqua 100-33Insulin Glargine/Lixisenatide22$19,260
JanumetSitagliptin Phos/Metformin Hcl12$18,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,497$277,255214 claims
AmgenProlia$2,425$106,75662 claims
Boehringer IngelheimJardiance$958$94,77159 claims
Novo NordiskOzempic, Rybelsus$884$83,81564 claims
MerckJanuvia, Janumet$704$77,11063 claims
Lilly USA, LLCMounjaro$877$53,87934 claims
PfizerEliquis, Paxlovid$585$53,51781 claims
BayerKerendia$718$33,85223 claims
AbbVieLinzess, Synthroid$422$24,19460 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →